Detection of Hepatits B virus mutations
Worldwide, it is estimated that 400 million people are chronically infected with hepatitis B virus (HBV). Chronic hepatitis B (CHB) infection is the commonest cause of liver cirrhosis and hepatocellular carcinoma (HCC), with an estimated 500,000‐900,000 death per year. Continuing HBV replication increases the risk of progression to cirrhosis and HCC. Thus, antiviral therapy aiming at blocking virus replication is essential in managing CHB patients. A number of nucleos(t)ide analogues such as lamivudine, adefovir dipivoxil, telbivudine, entecavir and tenofovir are approved for antiviral treatment.
Unfortunately, HBV variations frequently develop with long‐term antiviral therapy. Some of these variations confer drug resistance, resulting in treatment failure which may further lead to hepatitis reactivation and hepatic decompensation. Periodic HBV viral load quantification is commonly used to monitor antiviral treatment response and early detection of drug resistance. This invention discloses a method for direct detection of important HBV variations.
Page 1 of 1
Inventor: Ding, Chunming | Luan, Ju | Zhou, Boping | Yuan, Jing | Chen, Xinchun | Zhang, Hongmei
Priority Number: US8435764B2
IPC Current: C12P001934 | C07H002104 | C12Q000168
US Class: 4350912 | 43500612 | 43509133 | 5360243
Assignee Applicant: The Chinese University of Hong Kong | The Third People's Hospital of Shenzhen
Title: Multiplex detection of hepatitis virus variations
Usefulness: Multiplex detection of hepatitis virus variations
Summary: The method is useful for: detecting HV variations; and treating HV infection, where HV is a hepatitis-B virus (all claimed). Test details are described but no results given.
Novelty: Detecting hepatitis virus variations, comprises providing DNA molecule of hepatitis virus as a template from a subject with hepatitis virus infection, extending multiplex extension primers along template, and analyzing extension products
生物醫學
病原
09/MED/320
Inventor(s): Professor Chunming DING, Centre for Emerging Infectious Diseases
Patent Status: Licensing Status: US Patent Pending Available for licensing
香港
